普伐他汀对糖尿病大鼠肾脏病理学影响

目的 :研究普伐他汀对糖尿病大鼠肾脏病理学影响 ,探讨其对糖尿病肾病的保护作用。方法 :30只SD大鼠随机分为对照组、糖尿病组及普伐他汀组 ,以链脲佐菌素制备糖尿病大鼠模型。实验 12周末观察肾组织HE及PAS染色 ,采用医学病理图像分析系统测定肾小球面积 (GA)、系膜基质面积 (MA)、肾小球细胞定量指数 (MSC)。并测定尿白蛋白排泄率 (UAER)、血糖和血清胆固醇 (Tch)、甘油三酯 (TG)、低密度脂蛋白 (LDL)、血肌酐 (Scr)。结果 :普伐他汀组与糖尿病组比较 ,肾小球MSC和MA明显减少 (P <0 .0 5 ) ,但高于对照组 ;UAER (P <0 .0 1)、Tch、TG、LDL明显减少 (P <0 .0 5 ) ;血糖两组无差异性。Scr3组无差异性。结论 :普伐他汀能抑制肾小球系膜基质合成 ,延缓糖尿病大鼠肾脏病变的进展。

Effects of Pravastatin on Pathological Changes of Diabetic Rats

Objective: To study the effects of the Pravastatin on pathological changes in the renal cortex streptozotocin induced diabetic rats, and to investigate its possible protective mechanism. Methods: 30 female Sprague-Dawley rats were randomly divided into three groups (n = 10 per group): control group, diabete group, and Pravastatin group. In the 12th week, parts of the kidney were stained with HE and PAS, and mesangial cell index(MSC) and mesangial matrix area(MA) were assessed by medical pathological image analysis system. Serum lipid, serum sugar, serum creatine(Scr) and the urinary albumin excretive rate (UAER) were determined at the same time. Results: In comparison with those in diabete group, MSC(P<0.05),MA(P<0.05) and serum lipid(P<0.05), UAER(P<0.01)were lower in Pravastatin group. Meanwhile, serum sugar and Scr were not altered in both groups. Conclusion: Pravastatin may prevent the kidney pathological progress in diabetic nephropathy.